Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHV NASDAQ:RIGL NASDAQ:VSTM NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$2.55-2.3%$2.97$1.84▼$5.31$90.53M1.31.19 million shs401,123 shsRIGLRigel Pharmaceuticals$21.91+4.0%$19.75$8.61▼$29.82$376.39M1.21179,499 shs179,259 shsVSTMVerastem$6.08-1.5%$5.56$2.10▼$9.10$339.04M0.712.23 million shs2.02 million shsXOMAXOMA Royalty$24.77-0.4%$25.71$18.35▼$35.00$297.74M0.9335,060 shs20,821 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences-2.30%-4.85%+12.83%-0.78%-48.80%RIGLRigel Pharmaceuticals+4.04%+8.63%+17.48%+13.17%+107.09%VSTMVerastem-1.46%-0.98%+25.36%-18.17%+133.85%XOMAXOMA Royalty-0.44%-4.10%-5.13%+1.85%-7.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHVAchieve Life Sciences1.7798 of 5 stars3.82.00.00.01.10.00.6RIGLRigel Pharmaceuticals3.1918 of 5 stars3.20.00.00.03.21.73.1VSTMVerastem2.4638 of 5 stars3.51.00.00.02.82.50.6XOMAXOMA Royalty3.9209 of 5 stars3.54.00.03.00.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.33462.09% UpsideRIGLRigel Pharmaceuticals 2.40Hold$36.4066.13% UpsideVSTMVerastem 3.00Buy$13.38119.98% UpsideXOMAXOMA Royalty 3.00Buy$69.50180.58% UpsideCurrent Analyst Ratings BreakdownLatest ACHV, RIGL, VSTM, and XOMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025VSTMVerastemRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.005/28/2025XOMAXOMA RoyaltyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$104.005/9/2025VSTMVerastemHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $14.005/7/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $23.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/ARIGLRigel Pharmaceuticals$179.28M2.18$1.12 per share19.52$0.19 per share115.32VSTMVerastem$10M33.41N/AN/A($0.65) per share-9.35XOMAXOMA Royalty$13.05M22.72N/AN/A$6.95 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/7/2025 (Estimated)RIGLRigel Pharmaceuticals$17.49M$2.0710.5820.87N/A18.31%-655.26%24.47%8/5/2025 (Estimated)VSTMVerastem-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/7/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.15N/AN/AN/A-13.04%-12.43%-4.85%8/12/2025 (Estimated)Latest ACHV, RIGL, VSTM, and XOMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025XOMAXOMA Royalty-$0.12N/AN/AN/A$9.39 millionN/A8/7/2025Q2 2025ACHVAchieve Life Sciences-$0.34N/AN/AN/AN/AN/A8/7/2025Q2 2025VSTMVerastem-$0.64N/AN/AN/A$6.01 millionN/A8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.42N/AN/AN/A$64.58 millionN/A5/13/2025Q1 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/A5/13/2025Q1 2025VSTMVerastem-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A5/13/2025Q1 2025XOMAXOMA Royalty-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million5/6/2025Q1 2025RIGLRigel Pharmaceuticals$0.14$0.63+$0.49$0.63$43.87 million$53.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AVSTMVerastemN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.853.513.51RIGLRigel Pharmaceuticals2.422.202.13VSTMVerastemN/A3.503.50XOMAXOMA Royalty1.185.545.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%RIGLRigel Pharmaceuticals66.23%VSTMVerastem88.37%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%RIGLRigel Pharmaceuticals9.48%VSTMVerastem2.10%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2034.69 million33.64 millionOptionableRIGLRigel Pharmaceuticals16017.87 million16.18 millionOptionableVSTMVerastem5054.95 million53.80 millionOptionableXOMAXOMA Royalty1011.97 million10.88 millionOptionableACHV, RIGL, VSTM, and XOMA HeadlinesRecent News About These CompaniesWall Street Zen Upgrades XOMA Royalty (NASDAQ:XOMA) to BuyJuly 28, 2025 | americanbankingnews.comXOMA Royalty (NASDAQ:XOMA) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?July 26, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Upgraded by Wall Street Zen to "Buy" RatingJuly 26, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Shares Cross Above 200 Day Moving Average - Here's What HappenedJuly 18, 2025 | marketbeat.comResearch non-profit to acquire embattled Essa in Xoma Royalty-backed dealJuly 14, 2025 | fiercebiotech.comFESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionJuly 14, 2025 | prnewswire.comXOMA Royalty (NASDAQ:XOMA) Share Price Crosses Above 200 Day Moving Average - Here's WhyJuly 10, 2025 | marketbeat.comAcuitas Investments LLC Trims Stake in XOMA Royalty Corporation (NASDAQ:XOMA)July 2, 2025 | marketbeat.comTop biotech deals in June 2025July 2, 2025 | labiotech.euLXOMA Royalty to Buy Turnstone BiologicsJune 27, 2025 | marketwatch.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comXOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger DealJune 27, 2025 | quiverquant.comQTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightJune 27, 2025 | globenewswire.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?June 24, 2025 | zacks.comXOMA Preferred Shares Series A declares $0.539 dividendJune 18, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 18, 2025 | seekingalpha.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | investing.comXOMA Royalty Declares Quarterly Preferred Stock DividendsJune 18, 2025 | globenewswire.comPositive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy RatingMay 29, 2025 | tipranks.comXOMA boosts stake in anti-CD38 antibody with $30 million dealMay 28, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHV, RIGL, VSTM, and XOMA Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$2.55 -0.06 (-2.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.56 +0.02 (+0.59%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Rigel Pharmaceuticals NASDAQ:RIGL$21.91 +0.85 (+4.04%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$22.16 +0.25 (+1.14%) As of 08/1/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Verastem NASDAQ:VSTM$6.08 -0.09 (-1.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.10 +0.03 (+0.41%) As of 08/1/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.XOMA Royalty NASDAQ:XOMA$24.77 -0.11 (-0.44%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$24.73 -0.04 (-0.16%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
